肿瘤细胞治疗研究
英文原题：Harnessing nanoengineered CAR-T cell strategies to advance solid tumor immunotherapy.
嵌合抗原受体（CAR）T 细胞疗法在实体瘤治疗中的疗效和安全性仍未明确。
嵌合抗原受体（CAR）T细胞疗法治疗实体瘤的疗效和安全性仍未有定论。近年来，纳米技术已成为重塑CAR-T细胞疗法、改善治疗结局的一种有力策略。本文综述纳米工程化CAR-T细胞疗法应对现有挑战的潜力，包括CAR-T细胞工程的发展、肿瘤微环境（TME）调节，以及精准CAR-T治疗（精准靶向、监测和激活），并重点考虑临床转化。此外，文章还关注该领域日益发展的技术融合趋势，如mRNA疗法、类器官、新抗原和人工智能。研究者也特别强调纳米药物的安全性管理，以促进临床转化。
The efficacy and safety of chimeric antigen receptor (CAR) T cell therapy is still inconclusive in solid tumor treatment. Recently, nanotechnology has emerged as a potent strategy to reshape CAR-T cell therapy with promising outcomes. This review aims to discuss the significant potential of nano-engineered CAR-T cell therapy in addressing existing challenges, including CAR-T cell engineering evolution, tumor microenvironment (TME) modulation, and precise CAR-T cell therapy (precise targeting, monitoring, and activation), under the main consideration of clinical translation. It also focuses on the growing trend of technological convergence within this domain, such as mRNA therapeutics, organoids, neoantigen, and artificial intelligence. Moreover, safety management of nanomedicine is seriously emphasized to facilitate clinical translation.
MEMBER ACCOUNT
登录成功会直接打开下一页。
